Other · developed by AMGEN
AMG 691 is an agent given by subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06637371 | Phase 1 | Asthma | Active not recruiting | AMGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Asthma
Updated Nov 15, 2026. Something wrong or missing? Report it on the AMGN page.
See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AMGN catalysts and pipeline →